Cempra Inc (NASDAQ:CEMP) kicked into the New Year with a bang, by making announcement of its Phase 3 clinical trials of solithromycin by Toyama Chemical Co., Ltd. The FUJIFILM Holdings Corporation’s subsidiary, Toyama has exclusive R&D rights of Cempra’s solithromycin in Japan. Solithromycin is said to be Cempra’s lead product, which is licensed in Japan […]
